Jonas Oldgren

52.9k total citations · 10 hit papers
196 papers, 21.5k citations indexed

About

Jonas Oldgren is a scholar working on Cardiology and Cardiovascular Medicine, Internal Medicine and Surgery. According to data from OpenAlex, Jonas Oldgren has authored 196 papers receiving a total of 21.5k indexed citations (citations by other indexed papers that have themselves been cited), including 172 papers in Cardiology and Cardiovascular Medicine, 33 papers in Internal Medicine and 23 papers in Surgery. Recurrent topics in Jonas Oldgren's work include Atrial Fibrillation Management and Outcomes (140 papers), Antiplatelet Therapy and Cardiovascular Diseases (50 papers) and Cardiac Arrhythmias and Treatments (48 papers). Jonas Oldgren is often cited by papers focused on Atrial Fibrillation Management and Outcomes (140 papers), Antiplatelet Therapy and Cardiovascular Diseases (50 papers) and Cardiac Arrhythmias and Treatments (48 papers). Jonas Oldgren collaborates with scholars based in Sweden, United States and Germany. Jonas Oldgren's co-authors include Lars Wallentin, Stuart J. Connolly, Salim Yusuf, Michael D. Ezekowitz, Paul Reilly, John W. Eikelboom, Marco Alings, Hans‐Christoph Diener, Jeanne Varrone and Janice Pogue and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

Jonas Oldgren

193 papers receiving 20.7k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Dabigatran versus Warfarin in Patients with Atrial Fibrillation

2009 8.0k citations Stuart J. Connolly, Michael D. Ezekowitz et al. profile →
2016 ESC Guidelines for the Management of Atrial Fibrillation Developed in Collaboration With EACTS

2016 1.5k citations Paulus Kirchhof, Hans‐Christoph Diener et al. profile →
Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation

2017 843 citations Christopher P. Cannon, Deepak L. Bhatt et al. profile →
Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation

2011 822 citations John W. Eikelboom, Lars Wallentin et al. Circulation profile →
Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation

2015 745 citations Hein Heidbüchel, Peter Verhamme et al. EP Europace profile →
Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial

2010 728 citations Lars Wallentin, Salim Yusuf et al. profile →
European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation

2013 570 citations Hein Heidbüchel, Peter Verhamme et al. EP Europace profile →
Periprocedural Bleeding and Thromboembolic Events With Dabigatran Compared With Warfarin

2012 399 citations Jeff S. Healey, John W. Eikelboom et al. Circulation profile →
The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study

2016 330 citations Ziad Hijazi, Jonas Oldgren et al. profile →
The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation

2016 284 citations Ziad Hijazi, Johan Lindbäck et al. European Heart Journal profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jonas Oldgren Sweden	48	19.5k	8.3k	2.8k	1.7k	1.2k	196	21.5k
Paul Reilly United States	42	15.7k 0.8×	7.8k 0.9×	2.4k 0.8×	1.2k 0.7×	722 0.6×	128	17.5k
Janice Pogue Canada	42	14.7k 0.8×	4.7k 0.6×	2.9k 1.0×	2.0k 1.1×	853 0.7×	74	19.3k
Werner Hacke Germany	41	12.9k 0.7×	6.0k 0.7×	2.6k 0.9×	1.0k 0.6×	649 0.5×	117	14.3k
Rafael Díaz Argentina	45	12.7k 0.7×	4.1k 0.5×	1.9k 0.7×	3.1k 1.8×	1.0k 0.8×	130	18.4k
Marco Alings Netherlands	31	12.8k 0.7×	5.6k 0.7×	2.0k 0.7×	985 0.6×	555 0.4×	87	14.0k
Denis Xavier India	32	10.7k 0.5×	4.9k 0.6×	1.8k 0.6×	1.6k 0.9×	656 0.5×	103	13.6k
Brian F. Gage United States	55	9.7k 0.5×	3.5k 0.4×	2.2k 0.8×	1.9k 1.1×	938 0.8×	180	17.4k
Scott D. Berkowitz United States	54	13.6k 0.7×	8.8k 1.1×	1.9k 0.7×	3.3k 1.9×	637 0.5×	195	17.0k
Jun Zhu China	28	9.9k 0.5×	4.0k 0.5×	1.7k 0.6×	1.0k 0.6×	837 0.7×	133	11.3k
Jack Ansell United States	62	11.7k 0.6×	7.5k 0.9×	1.7k 0.6×	2.5k 1.4×	352 0.3×	225	16.4k

Countries citing papers authored by Jonas Oldgren

Since Specialization

Citations

This map shows the geographic impact of Jonas Oldgren's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jonas Oldgren with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jonas Oldgren more than expected).

Fields of papers citing papers by Jonas Oldgren

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jonas Oldgren. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jonas Oldgren. The network helps show where Jonas Oldgren may publish in the future.

Co-authorship network of co-authors of Jonas Oldgren

This figure shows the co-authorship network connecting the top 25 collaborators of Jonas Oldgren. A scholar is included among the top collaborators of Jonas Oldgren based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jonas Oldgren. Jonas Oldgren is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wallentin, Lars, Johan Lindbäck, Ziad Hijazi, et al.. (2025). Biomarker-Based Model for Prediction of Ischemic Stroke in Patients With Atrial Fibrillation. Journal of the American College of Cardiology. 85(11). 1173–1185. 1 indexed citations

Hijazi, Ziad, Lars Wallentin, Håkan Arheden, et al.. (2025). Rationale and design of a registry-based randomized controlled study of personalized biomarker-based risk score-guided stroke prevention treatment in atrial fibrillation. American Heart Journal. 290. 161–169. 1 indexed citations

Oldgren, Jonas, Ziad Hijazi, Håkan Arheden, et al.. (2025). Biomarker-Based ABC-AF Risk Scores for Personalized Treatment to Reduce Stroke or Death in Atrial Fibrillation: A Registry-Based, Multicenter, Randomized, Controlled Study. Circulation. 152(21). 1457–1469.

Buccheri, Sergio, Stefan James, Marion Mafham, et al.. (2025). Large simple randomized controlled trials—from drugs to medical devices: lessons from recent experience. Trials. 26(1). 24–24. 1 indexed citations

Lindbäck, Johan, Alexander P. Benz, John W. Eikelboom, et al.. (2024). Neuroglial Biomarkers for Risk Assessment of Ischemic Stroke and Other Cardiovascular Events in Patients With Atrial Fibrillation Not Receiving Oral Anticoagulation. Journal of the American Heart Association. 14(2). e038860–e038860. 1 indexed citations

Held, Claes, Nermin Hadziosmanovic, Johan Lindbäck, et al.. (2021). Risk markers of incident atrial fibrillation in patients with coronary heart disease. American Heart Journal. 233. 92–101. 6 indexed citations

Caterina, Raffaele De, Dimitar Raev, Shamir R. Mehta, et al.. (2020). Comparison of Dabigatran Plus a P2Y12 Inhibitor With Warfarin-Based Triple Therapy Across Body Mass Index in RE-DUAL PCI. The American Journal of Medicine. 133(11). 1302–1312. 3 indexed citations

Hijazi, Ziad, Paolo Verdecchia, Jonas Oldgren, et al.. (2019). Cardiac biomarkers and left ventricular hypertrophy in relation to outcomes in patients with atrial fibrillation: Experiences from the RE-LY trial. IrInSubria (University of Insubria). 15 indexed citations

Mauri, Laura, Deepak L. Bhatt, Stefan H. Hohnloser, et al.. (2018). P3180The effect of PCI complexity on the efficacy and safety of dabigatran dual therapy vs warfarin triple therapy in atrial fibrillation: a subgroup analysis from the RE-DUAL PCI trial. European Heart Journal. 39(suppl_1). 1 indexed citations

10.

Sundström, Johan, et al.. (2017). Low-Dose Aspirin Discontinuation and Risk of Cardiovascular Events. Circulation. 136(13). 1183–1192. 80 indexed citations

11.

Heidbüchel, Hein, Peter Verhamme, Marco Alings, et al.. (2016). Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: Executive summary. European Heart Journal. 38(27). ehw058–ehw058. 188 indexed citations

12.

Norrving, Bo, et al.. (2016). Abstract 18795: Non-Vitamin K Oral Anticoagulants Are Non-Inferior for Stroke Prevention but Cause Fewer Major Bleedings Than Well-Managed Warfarin With Time in Therapeutic Range 70% or Higher in Sweden. Circulation. 1 indexed citations

13.

Terént, Andreas, Signild Åsberg, Jonas Oldgren, Ziad Hijazi, & Bo Norrving. (2016). Antikoagulantia efter akut ischemisk stroke med förmaksflimmer - Frågan om rätt tidpunkt för insättning kräver randomiserad klinisk prövning.. Läkartidningen. 113. 1 indexed citations

14.

Heidbüchel, Hein, Peter Verhamme, Marco Alings, et al.. (2015). Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. EP Europace. 17(10). 1467–1507. 745 indexed citations breakdown →

15.

Douketis, J., Martina Brueckmann, Mandy Fraessdorf, et al.. (2015). Bleeding and thromboembolic outcomes in warfarin-and dabigatran-treated patients in the RE-LY trial who required an urgent surgery or procedure. Journal of Thrombosis and Haemostasis. 13. 393–394. 1 indexed citations

16.

Hijazi, Ziad, Jonas Oldgren, Ulrika Andersson, et al.. (2012). Cardiac Biomarkers Are Associated With an Increased Risk of Stroke and Death in Patients With Atrial Fibrillation. Circulation. 125(13). 1605–1616. 304 indexed citations

17.

Connolly, Stuart J., Paul Reilly, Janice Pogue, et al.. (2012). Randomized Comparison of the Effects of Two Doses of Dabigatran Etexilate on Clinical Outcomes Over 4.3 Years : Results of the Rely-Able Double-Blind Randomized Trial. Circulation. 126(23). 2793–2793. 6 indexed citations

18.

Healey, Jeff S., John W. Eikelboom, James D. Douketis, et al.. (2012). Periprocedural Bleeding and Thromboembolic Events With Dabigatran Compared With Warfarin. Circulation. 126(3). 343–348. 399 indexed citations breakdown →

19.

Dans, Antonio L., Stuart J. Connolly, Lars Wallentin, et al.. (2012). Concomitant Use of Antiplatelet Therapy with Dabigatran or Warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Trial. Circulation. 127(5). 634–640. 344 indexed citations

20.

Healey, Jeff S., John W. Eikelboom, Lars Wallentin, et al.. (2011). Abstract 12041: The Risk of Peri-Operative Bleeding with Warfarin Compared to Two Doses of Dabigatran: Results From the RE-LY Trial. Circulation. 124. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact